ConductScience.org, home

Paper16487232

Orphan drug development is progressing too slowly.

Joppi R and 2 others. Br J Clin Pharmacol, 2006. Cited by 48 papers, by iCite.

Cite this record

ConductScience Library. Orphan drug development is progressing too slowly. Papers, record 16487232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16487232

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Orphan drug development is progressing too slowly.
PubMed
Journal
Br J Clin Pharmacol
PubMed
Year
2006
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
48
iCite
Relative citation ratio, by iCite
1.22
iCite
Revised in PubMed
2009-10-02
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Joppi RRoberta
2Bertele VVittorio
3Garattini SSilvio

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Drug IndustryMajor topic
Pharmaceutical PreparationsMajor topic
Animals
Documentation
European Union
Health Systems Agencies
Research
Retrospective Studies

Source PubMed

Download CSV of topics

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in16487216Rare diseases and orphan drugs.https://conductscience.org/library/papers/16487216

Source PubMed

Download CSV of comments and corrections

Cited by25

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 48 citations.

PMIDTitleJournalYearIn PapersSource
42185862Rare disease patients protection: theoretical discussion and institutional construction of orphan drug designation in China.Orphanet J Rare Dis2026https://conductscience.org/library/papers/42185862PubMed
38778810Pharmaceutical policy and innovation for rare diseases: A narrative review.F1000Res2023https://conductscience.org/library/papers/38778810PubMed
38523639Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries.Front Pharmacol2024https://conductscience.org/library/papers/38523639PubMed
37325577Evaluation of clinical trials done for orphan drugs versus nonorphan drugs in infectious diseasesan eleven year analysis [2010-2020].Perspect Clin Res2023https://conductscience.org/library/papers/37325577PubMed
34287806The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging.Eur J Drug Metab Pharmacokinet2021https://conductscience.org/library/papers/34287806PubMed
31364772Survey of Japanese Orphan Drug Program: Factors Related to Successful Marketing Approval.J Clin Pharmacol2020https://conductscience.org/library/papers/31364772PubMed
30400970Recommendations for the design of small population clinical trials.Orphanet J Rare Dis2018https://conductscience.org/library/papers/30400970PubMed
29788976Improving the analysis of composite endpoints in rare disease trials.Orphanet J Rare Dis2018https://conductscience.org/library/papers/29788976PubMed
27600717The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe.Orphanet J Rare Dis2016https://conductscience.org/library/papers/27600717PubMed
27301273Directions for new developments on statistical design and analysis of small population group trials.Orphanet J Rare Dis2016https://conductscience.org/library/papers/27301273PubMed
26511061Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments.Orphanet J Rare Dis2015https://conductscience.org/library/papers/26511061PubMed
23109143Unintended effects of orphan product designation for rare neurological diseases.Ann Neurol2012https://conductscience.org/library/papers/23109143PubMed
23090701Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.Eur J Clin Pharmacol2013https://conductscience.org/library/papers/23090701PubMed
23040887Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.J Allergy Clin Immunol2013https://conductscience.org/library/papers/23040887PubMed
21892964Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?Orphanet J Rare Dis2011https://conductscience.org/library/papers/21892964PubMed
21842335Time to revisit the orphan drug law.Eur J Clin Pharmacol2012https://conductscience.org/library/papers/21842335PubMed
21395641Access to orphan drugs despite poor quality of clinical evidence.Br J Clin Pharmacol2011https://conductscience.org/library/papers/21395641PubMed
21073206
Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.
Pharmacoeconomics2011https://conductscience.org/library/papers/21073206PubMed
20624867Policy alternatives for treatments for rare diseases.CMAJ2010https://conductscience.org/library/papers/20624867PubMed
20082539Safety-related regulatory actions for orphan drugs in the US and EU: a cohort study.Drug Saf2010https://conductscience.org/library/papers/20082539PubMed

See all 25 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/16487232

GET https://conductscience.org/api/papers/v1/16487232/cited_by?page=2